Celiac Disease Research Center, Faculty of Medicine and Life Sciences, University of Tampere, Tampere, Finland.
Tampere Center for Child Health Research, University of Tampere, and Department of Paediatrics, Tampere University Hospital, Tampere, Finland.
Aliment Pharmacol Ther. 2019 Feb;49(3):277-284. doi: 10.1111/apt.15109. Epub 2018 Dec 27.
BACKGROUND: The revised paediatric criteria for coeliac disease allow omission of duodenal biopsies in symptomatic children who have specific serology and coeliac disease-associated genetics. It remains unclear whether this approach is also applicable for adults with various clinical presentations. AIM: To evaluate the accuracy of serology-based criteria in adults with variable pre-test probabilities for coeliac disease. METHODS: Three study cohorts comprised adults with high-risk clinical coeliac disease suspicion (n = 421), moderate-risk family members of coeliac disease patients (n = 2357), and low-risk subjects from the general population (n = 2722). Serological and clinical data were collected, and "triple criteria" for coeliac disease comprised transglutaminase 2 antibodies >10× the upper limit of normal, positive endomysium antibodies, and appropriate genetics without requirement of symptoms. The diagnosis was based on intestinal biopsy. RESULTS: The diagnosis of coeliac disease was established in 274 subjects. Of these, 59 high-risk subjects, 17 moderate-risk subjects, and 14 low-risk subjects fulfilled the "triple criteria". All had histologically proven coeliac disease, giving the criteria a positive predictive value of 100%. Altogether, 90 (33%) of all 274 newly diagnosed patients could have avoided biopsy, including 37% among high-risk, 20% among moderate-risk, and 48% among low-risk patients. No histological findings other than coeliac disease were found in the biopsies of "triple positive" subjects. CONCLUSIONS: Coeliac disease can reliably and safely be diagnosed without biopsy in adults fulfilling the "triple criteria" regardless of the pre-test probability. Revised criteria would enable the number of endoscopies to be reduced by one-third.
背景:修订后的儿科乳糜泻诊断标准允许在有特定血清学和乳糜泻相关遗传学证据的症状性儿童中省略十二指肠活检。目前尚不清楚这种方法是否也适用于具有各种临床表现的成人。
目的:评估基于血清学的标准在具有不同乳糜泻先验概率的成人中的准确性。
方法:三个研究队列包括具有高风险乳糜泻临床可疑性的成人(n=421)、乳糜泻患者的中度风险亲属(n=2357)和一般人群中的低风险受试者(n=2722)。收集血清学和临床数据,乳糜泻的“三联标准”包括转谷氨酰胺酶 2 抗体高于正常值的 10 倍、阳性内肌抗体和适当的遗传学,而无需症状。诊断基于肠活检。
结果:在 274 名受试者中确立了乳糜泻的诊断。其中,59 名高风险受试者、17 名中风险受试者和 14 名低风险受试者符合“三联标准”。所有受试者均有组织学证实的乳糜泻,因此该标准的阳性预测值为 100%。总共,274 名新诊断的患者中有 90 名(33%)可以避免活检,包括高风险患者的 37%、中风险患者的 20%和低风险患者的 48%。“三联阳性”受试者的活检中未发现除乳糜泻以外的其他组织学发现。
结论:在符合“三联标准”的成人中,无论先验概率如何,都可以可靠且安全地在不进行活检的情况下诊断乳糜泻。修订后的标准可使内窥镜检查的数量减少三分之一。
Aliment Pharmacol Ther. 2018-12-27
Arab J Gastroenterol. 2016-6
Gastroenterology. 2017-6-15
Best Pract Res Clin Gastroenterol. 2015-6
J Pediatr Gastroenterol Nutr. 2020-1
Eur J Gastroenterol Hepatol. 2003-9
Front Pediatr. 2025-3-20
Aliment Pharmacol Ther. 2025-6
Turk J Gastroenterol. 2024-8-2
Gastroenterol Hepatol Bed Bench. 2023
Gastroenterol Hepatol Bed Bench. 2023
Frontline Gastroenterol. 2022-8-11
Frontline Gastroenterol. 2022-9-22